OraSure (OSUR) 10-Q7 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 04, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'OSUR	'
Entity Registrant Name	'ORASURE TECHNOLOGIES INC	'
Entity Central Index Key	'0001116463	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	56,056,813

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS:	'	'
Cash	$93,855	$93,191
Short-term investments	5,000	'
Accounts receivable, net of allowance for doubtful accounts of $288 and $299	14,920	12,957
Inventories	14,843	11,444
Prepaid expenses	1,089	1,712
Deferred income taxes	67	71
Other current assets	273	200
Total current assets	130,047	119,575
PROPERTY AND EQUIPMENT, net	17,958	17,933
INTANGIBLE ASSETS, net	18,831	22,226
GOODWILL	22,562	23,782
OTHER ASSETS	1,102	729
TOTAL ASSETS	190,500	184,245
CURRENT LIABILITIES:	'	'
Accounts payable	4,510	4,834
Deferred revenue	11,540	1,119
Accrued expenses	9,203	13,032
Total current liabilities	25,253	18,985
OTHER LIABILITIES	1,090	677
DEFERRED INCOME TAXES	3,233	3,437
COMMITMENTS AND CONTINGENCIES (Note 6)	'	'
STOCKHOLDERS' EQUITY	'	'
Preferred stock, par value $.000001, 25,000 shares authorized, none issued	'	'
Common stock, par value $.000001, 120,000 shares authorized, 56,052 and 55,632 shares issued and outstanding	'	'
Additional paid-in capital	342,865	338,674
Accumulated other comprehensive loss	-6,248	-3,797
Accumulated deficit	-175,693	-173,731
Total stockholders' equity	160,924	161,146
Total liabilities and stockholders' equity	$190,500	$184,245

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Allowance for doubtful accounts	$288	$299
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	120,000	120,000
Common stock, shares issued	56,052	55,632
Common stock, shares outstanding	56,052	55,632

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
NET REVENUES:	'	'	'	'
Product	$24,447	$24,524	$73,610	$69,549
Licensing and product development	3,398	147	4,173	623
Total revenue	27,845	24,671	77,783	70,172
COST OF PRODUCTS SOLD	9,140	9,738	29,135	28,711
Gross profit	18,705	14,933	48,648	41,461
OPERATING EXPENSES:	'	'	'	'
Research and development	2,990	2,670	8,242	8,720
Sales and marketing	9,216	8,981	30,828	35,224
General and administrative	5,617	5,342	17,317	15,742
Gain on contract termination settlement	'	'	-5,500	'
Total operating expenses	17,823	16,993	50,887	59,686
Operating income (loss)	882	-2,060	-2,239	-18,225
OTHER INCOME	268	41	244	36
Income (loss) before income taxes	1,150	-2,019	-1,995	-18,189
INCOME TAX EXPENSE (BENEFIT)	10	-127	-33	-786
NET INCOME (LOSS)	$1,140	($1,892)	($1,962)	($17,403)
EARNINGS (LOSS) PER SHARE:	'	'	'	'
BASIC	$0.02	($0.03)	($0.04)	($0.31)
DILUTED	$0.02	($0.03)	($0.04)	($0.31)
SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE:	'	'	'	'
BASIC	56,018	55,592	55,897	55,534
DILUTED	56,666	55,592	55,897	55,534

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
NET INCOME (LOSS)	$1,140	($1,892)	($1,962)	($17,403)
OTHER COMPREHENSIVE INCOME (LOSS)	'	'	'	'
Currency translation adjustments	-2,295	876	-2,451	-1,709
Other comprehensive income (loss)	-2,295	876	-2,451	-1,709
COMPREHENSIVE LOSS	($1,155)	($1,016)	($4,413)	($19,112)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
OPERATING ACTIVITIES:	'	'
Net loss	($1,962)	($17,403)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'
Stock-based compensation	4,284	4,187
Depreciation and amortization	4,732	4,846
Unrealized foreign currency loss	-73	'
Deferred income taxes	-33	-786
Changes in assets and liabilities	'	'
Accounts receivable	-2,111	3,127
Inventories	-3,444	745
Prepaid expenses and other assets	576	-554
Accounts payable	-284	497
Deferred revenue	10,433	-1,098
Accrued expenses and other liabilities	-3,734	3,297
Net cash provided by (used in) operating activities	8,384	-3,142
INVESTING ACTIVITIES:	'	'
Purchases of short term investments	-9,407	'
Proceeds from maturities of short term investments	4,432	'
Purchases of property and equipment	-2,353	-1,696
Net cash used in investing activities	-7,328	-1,696
FINANCING ACTIVITIES:	'	'
Proceeds from exercise of stock options	546	317
Repurchase of common stock	-639	-817
Net cash used in financing activities	-93	-500
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	-299	40
NET INCREASE (DECREASE) IN CASH	664	-5,298
CASH, BEGINNING OF PERIOD	93,191	87,888
CASH, END OF PERIOD	93,855	82,590
Cash paid for:	'	'
Income taxes	$42	$28

The_Company

The Company	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
The Company	'
	1	The Company
	We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our OTC HIV and cryosurgical products are available at retail pharmacies and mass merchandisers, and our OTC HIV product is also sold to consumers over the internet.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
	Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
	The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results of operations expected for the full year.
	Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
	Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

	Our available-for-sale securities as of September 30, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities.
	Fair Value of Financial Instruments. As of September 30, 2014, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.
	Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2014 and December 31, 2013 was $1,090 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.
	All of our available-for-sale securities were classified and measured as Level 1 instruments as of September 30, 2014.
	Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


			September 30, 2014				December 31, 2013
	Raw materials		$	6,772			$	6,700
	Work in process			937				833
	Finished goods			7,134				3,911

			$	14,843			$	11,444

	Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of September 30, 2014 and December 31, 2013 was $30,603 and $28,390, respectively.

	Intangible Assets. Intangible assets consist of the following:


					September 30, 2014
			Amortization		Gross				Accumulated				Net
			Period (Years)		Gross				Amortization				Net
	Customer list		10		$	11,190			$	(3,370	)		$	7,820
	Patents and product rights		10-Mar			10,449				(7,844	)			2,605
	Acquired technology		7			8,692				(3,682	)			5,010
	Tradename		15			4,289				(893	)			3,396

					$	34,620			$	(15,789	)		$	18,831


					31-Dec-13
			Amortization		Gross				Accumulated				Net
			Period(Years)		Gross				Amortization				Net
	Customer list		10		$	11,795			$	(2,701	)		$	9,094
	Patents and product rights		10-Mar			10,449				(7,466	)			2,983
	Acquired technology		7			9,162				(2,952	)			6,210
	Tradename		15			4,521				(715	)			3,806
	Non-compete agreements		3-Jan			787				(654	)			133

					$	36,714			$	(14,488	)		$	22,226

	Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.
	We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2014, we believe no indicators of impairment exist.
	The change in goodwill from $23,782 as of December 31, 2013 to $22,562 as of September 30, 2014 is a result of foreign currency translation.
	Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV test, we do not grant price protection or product return rights to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

	We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result, initially we did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first nine months of 2014 were recorded based upon shipments into the distribution channel, while revenues in the first nine months of 2013 were recorded based upon the consummation of a sale to the consumer.
	Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as licensing and product development revenue in our statements of operations.
	We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.
	On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV Rapid Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets.
	Under the terms of our agreement, we have granted exclusive promotion rights to AbbVie for the OraQuick® HCV Rapid test in certain markets and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick® HCV Rapid test. We have also jointly agreed with AbbVie to co-promote our OraQuick® HCV Rapid test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services.
	In exchange for these exclusive rights and other services, we will receive up to $75,000 in payments over the term of the agreement which expires on December 31, 2019. We will recognize revenues from these periodic payments ratably, over the life of the agreement. In addition, if certain performance-based milestones are achieved, we could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations.

Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September 30, 2014 and December 31, 2013, the reserve for sales returns and allowances was $398 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.
Termination Settlement. On November 21, 2013, we terminated our assay development collaboration with Roche Diagnostics (“Roche”). Pursuant to a termination agreement, Roche paid us $8,300 which was recorded as a reduction of operating expense in our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to continue to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, have recorded $5,500 as a reduction of operating expense in our consolidated statement of operations.
Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at September 30, 2014 and December 31, 2013 includes customer prepayments of $713 and $1,119, respectively. Deferred revenue also includes $10,827 which represents the $15,000 payment received in July 2014 under the terms of our HCV collaboration with AbbVie, less amounts recognized ratably in revenue.
Customer and Vendor Concentrations. We had no significant concentrations (greater than 10%) in accounts receivable as of September 30, 2014. One of our customers, AbbVie, accounted for approximately 12% of our net revenues for the three months ended September 30, 2014. We had no significant concentrations (greater than 10%) in net revenues for the nine months ended September 30, 2014 and the three or nine months ended September 30, 2013.
We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings (loss) per share are as follows:


		Three Months								Nine Months
		Ended September 30,								Ended September 30,
		2014				2013				2014				2013
Net income (loss)		$	1,140			$	(1,892	)		$	(1,962	)		$	(17,403	)

Weighted average shares of common stock outstanding:
Basic			56,018				55,592				55,897				55,534
Dilutive effect of stock options and restricted stock			648				—				—				—

Diluted			56,666				55,592				55,897				55,534

Earnings (loss) per share:
Basic		$	0.02			$	(0.03	)		$	(0.04	)		$	(0.31	)

Diluted		$	0.02			$	(0.03	)		$	(0.04	)		$	(0.31	)

For the three-month periods ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 2,647 and 5,499 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 3,313 and 5,324 shares, respectively, were similarly excluded from the computation of diluted earnings (loss) per share.
Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.
Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.
We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $2,451 and $1,709 currency translation adjustments recorded in the first nine months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.
Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We will evaluate the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	3	Stockholders’ Equity
	Stock-Based Awards
	We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue new restricted stock, we normally issue new shares rather than purchase shares on the open market.
	Total compensation cost related to stock options for the nine months ended September 30, 2014 and 2013 was $2,286 and $2,028, respectively. Net cash proceeds from the exercise of stock options were $546 and $317 for the nine months ended September 30, 2014 and 2013, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.
	Compensation cost of $1,998 and $2,159 related to restricted shares was recognized during the nine months ended September 30, 2014 and 2013, respectively. In connection with the vesting of restricted shares, during the nine months ended September 30, 2014 and 2013, 106 and 122 shares, respectively, with aggregate values of $639 and $817, respectively, were withheld and retired in satisfaction of minimum tax withholding obligations.

Accrued_Expenses

Accrued Expenses	9 Months Ended
Accrued Expenses	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	4	Accrued Expenses


			September 30, 2014		December 31, 2013
	Payroll and related benefits		$	5,093	$	5,827
	Royalties			1,703		4,374
	Professional fees			484		749
	Other			1,923		2,082

			$	9,203	$	13,032

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	5	Income Taxes
	During the three months ended September 30, 2014, we recorded foreign deferred tax expense of $10. During the nine months ended September 30, 2014, we recorded foreign deferred tax benefits of $33. During the three and nine months ended September 30, 2013, we recorded foreign deferred tax benefits of $127 and $786, respectively. The foreign deferred tax benefits are associated with certain Canadian research and development and investment tax credits. The income tax benefits associated with DNAG are considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.
	Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of September 30, 2014 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.
	In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of September 30, 2014 and December 31, 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three and nine month periods ended September 30, 2014 and 2013.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	6	Commitments and Contingencies
	From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

Business_Segment_Information

Business Segment Information	9 Months Ended
Business Segment Information	Sep. 30, 2014
Segment Reporting [Abstract]	'
Business Segment Information	'
	7	Business Segment Information
	We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products result from sales to retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.
	We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.

	The following table summarizes segment information for the three and nine months ended September 30, 2014 and 2013:


			Three Months Ended September 30,							Nine Months Ended September 30,
			2014				2013			2014			2013
	Net revenues:
	OSUR		$	20,978			$	19,707		$	60,260		$	56,622
	DNAG			6,867				4,964			17,523			13,550

	Total		$	27,845			$	24,671		$	77,783		$	70,172

	Operating income (loss):
	OSUR		$	(987	)		$	(2,516	)	$	(5,177	)	$	(18,012	)
	DNAG			1,869				456			2,938			(213	)

	Total		$	882			$	(2,060	)	$	(2,239	)	$	(18,225	)

	Depreciation and amortization:
	OSUR		$	820			$	815		$	2,386		$	2,389
	DNAG			804				810			2,346			2,457

	Total		$	1,624			$	1,625		$	4,732		$	4,846

	Capital expenditures:
	OSUR		$	298			$	369		$	1,868		$	1,096
	DNAG			67				235			485			600

	Total		$	365			$	604		$	2,353		$	1,696



			September 30, 2014				December 31, 2013
	Total assets:
	OSUR		$	137,418			$	130,848
	DNAG			53,082				53,397

	Total		$	190,500			$	184,245

	Our products are sold principally in the United States and Europe.
	The following table represents total revenues by geographic area, based on the location of the customer:


			Three Months Ended September 30,							Nine Months Ended September 30,
			2014				2013			2014			2013
	United States		$	22,469			$	19,052		$	58,987		$	54,052
	Europe			3,252				2,540			10,935			7,823
	Other regions			2,124				3,079			7,861			8,297

			$	27,845			$	24,671		$	77,783		$	70,172


	The following table represents total long-lived assets by geographic area:


			September 30, 2014				December 31, 2013
	United States		$	16,802			$	16,925
	Canada			1,139				975
	Other regions			17				33

		$	17,958			$	17,933

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation and Basis of Presentation	'
	Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
	The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results of operations expected for the full year.
Use of Estimates	'
Use of Estimates	Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
Short-Term Investments	'
	Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

	Our available-for-sale securities as of September 30, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments. As of September 30, 2014, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.
	Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of September 30, 2014 and December 31, 2013 was $1,090 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.
	All of our available-for-sale securities were classified and measured as Level 1 instruments as of September 30, 2014.
Inventories	'
	Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


		September 30, 2014				December 31, 2013
	Raw materials	$	6,772			$	6,700
	Work in process		937				833
	Finished goods		7,134				3,911

		$	14,843			$	11,444

Property and Equipment	'
Property and Equipment	Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of September 30, 2014 and December 31, 2013 was $30,603 and $28,390, respectively.
Intangible Assets	'
	Intangible Assets. Intangible assets consist of the following:


				September 30, 2014
		Amortization		Gross				Accumulated				Net
		Period (Years)		Gross				Amortization				Net
	Customer list	10		$	11,190			$	(3,370	)		$	7,820
	Patents and product rights	10-Mar			10,449				(7,844	)			2,605
	Acquired technology	7			8,692				(3,682	)			5,010
	Tradename	15			4,289				(893	)			3,396

				$	34,620			$	(15,789	)		$	18,831


				31-Dec-13
		Amortization		Gross				Accumulated				Net
		Period(Years)		Gross				Amortization				Net
	Customer list	10		$	11,795			$	(2,701	)		$	9,094
	Patents and product rights	10-Mar			10,449				(7,466	)			2,983
	Acquired technology	7			9,162				(2,952	)			6,210
	Tradename	15			4,521				(715	)			3,806
	Non-compete agreements	3-Jan			787				(654	)			133

				$	36,714			$	(14,488	)		$	22,226

Goodwill	'
	Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair value of the applicable reporting unit with its aggregate carrying value, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.
	We performed our last annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of September 30, 2014, we believe no indicators of impairment exist.
	The change in goodwill from $23,782 as of December 31, 2013 to $22,562 as of September 30, 2014 is a result of foreign currency translation.
Revenue Recognition	'
	Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV test, we do not grant price protection or product return rights to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

	We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result, initially we did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first nine months of 2014 were recorded based upon shipments into the distribution channel, while revenues in the first nine months of 2013 were recorded based upon the consummation of a sale to the consumer.
	Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statements of operations.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee and is recorded as licensing and product development revenue in our statements of operations.
	We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.
	On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV Rapid Test in the United States. The product will be used to test individuals at-risk for the hepatitis C virus (“HCV”). We will be responsible for manufacturing and selling the product into all markets.
	Under the terms of our agreement, we have granted exclusive promotion rights to AbbVie for the OraQuick® HCV Rapid test in certain markets and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick® HCV Rapid test. We have also jointly agreed with AbbVie to co-promote our OraQuick® HCV Rapid test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services.
	In exchange for these exclusive rights and other services, we will receive up to $75,000 in payments over the term of the agreement which expires on December 31, 2019. We will recognize revenues from these periodic payments ratably, over the life of the agreement. In addition, if certain performance-based milestones are achieved, we could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations.
Customer Sales Returns and Allowances	'
Customer Sales Returns and Allowances	Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September 30, 2014 and December 31, 2013, the reserve for sales returns and allowances was $398 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.
Termination Settlement	'
Termination Settlement	Termination Settlement. On November 21, 2013, we terminated our assay development collaboration with Roche Diagnostics (“Roche”). Pursuant to a termination agreement, Roche paid us $8,300 which was recorded as a reduction of operating expense in our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to continue to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5,500 depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, have recorded $5,500 as a reduction of operating expense in our consolidated statement of operations.
Deferred Revenue	'
Deferred Revenue	Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at September 30, 2014 and December 31, 2013 includes customer prepayments of $713 and $1,119, respectively. Deferred revenue also includes $10,827 which represents the $15,000 payment received in July 2014 under the terms of our HCV collaboration with AbbVie, less amounts recognized ratably in revenue.
Customer and Vendor Concentrations	'
	Customer and Vendor Concentrations. We had no significant concentrations (greater than 10%) in accounts receivable as of September 30, 2014. One of our customers, AbbVie, accounted for approximately 12% of our net revenues for the three months ended September 30, 2014. We had no significant concentrations (greater than 10%) in net revenues for the nine months ended September 30, 2014 and the three or nine months ended September 30, 2013.
	We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Earnings (Loss) Per Share	'
	Earnings (Loss) Per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options and unvested restricted stock, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

	The computations of basic and diluted earnings (loss) per share are as follows:


		Three Months								Nine Months
		Ended September 30,								Ended September 30,
		2014				2013				2014				2013
	Net income (loss)	$	1,140			$	(1,892	)		$	(1,962	)		$	(17,403	)

	Weighted average shares of common stock outstanding:
	Basic		56,018				55,592				55,897				55,534
	Dilutive effect of stock options and restricted stock		648				—				—				—

	Diluted		56,666				55,592				55,897				55,534

	Earnings (loss) per share:
	Basic	$	0.02			$	(0.03	)		$	(0.04	)		$	(0.31	)

	Diluted	$	0.02			$	(0.03	)		$	(0.04	)		$	(0.31	)

	For the three-month periods ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 2,647 and 5,499 shares, respectively, were excluded from the computation of diluted earnings (loss) per share, as their inclusion would have been anti-dilutive. For the nine months ended September 30, 2014 and 2013, outstanding common stock options and unvested restricted stock, representing 3,313 and 5,324 shares, respectively, were similarly excluded from the computation of diluted earnings (loss) per share.
Foreign Currency Translation	'
	Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
	Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.
Accumulated Other Comprehensive Loss	'
	Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.
	We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $2,451 and $1,709 currency translation adjustments recorded in the first nine months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars.
Recent Accounting Pronouncements	'
Recent Accounting Pronouncements	Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We will evaluate the effects, if any, which adoption of this guidance will have on our consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2014
Accounting Policies [Abstract]	'
Inventories	'
	Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


		September 30, 2014				December 31, 2013
	Raw materials	$	6,772			$	6,700
	Work in process		937				833
	Finished goods		7,134				3,911

		$	14,843			$	11,444

Summary of Intangible Assets	'
	Intangible assets consist of the following:


				September 30, 2014
		Amortization		Gross				Accumulated				Net
		Period (Years)		Gross				Amortization				Net
	Customer list	10		$	11,190			$	(3,370	)		$	7,820
	Patents and product rights	10-Mar			10,449				(7,844	)			2,605
	Acquired technology	7			8,692				(3,682	)			5,010
	Tradename	15			4,289				(893	)			3,396

				$	34,620			$	(15,789	)		$	18,831


				31-Dec-13
		Amortization		Gross				Accumulated				Net
		Period(Years)		Gross				Amortization				Net
	Customer list	10		$	11,795			$	(2,701	)		$	9,094
	Patents and product rights	10-Mar			10,449				(7,466	)			2,983
	Acquired technology	7			9,162				(2,952	)			6,210
	Tradename	15			4,521				(715	)			3,806
	Non-compete agreements	3-Jan			787				(654	)			133

				$	36,714			$	(14,488	)		$	22,226

Computations of Basic and Diluted Earnings (Loss) per Share	'
	The computations of basic and diluted earnings (loss) per share are as follows:


		Three Months								Nine Months
		Ended September 30,								Ended September 30,
		2014				2013				2014				2013
	Net income (loss)	$	1,140			$	(1,892	)		$	(1,962	)		$	(17,403	)

	Weighted average shares of common stock outstanding:
	Basic		56,018				55,592				55,897				55,534
	Dilutive effect of stock options and restricted stock		648				—				—				—

	Diluted		56,666				55,592				55,897				55,534

	Earnings (loss) per share:
	Basic	$	0.02			$	(0.03	)		$	(0.04	)		$	(0.31	)

	Diluted	$	0.02			$	(0.03	)		$	(0.04	)		$	(0.31	)

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
Accrued Expenses (Tables)	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Expenses	'

		September 30, 2014		December 31, 2013
	Payroll and related benefits	$	5,093	$	5,827
	Royalties		1,703		4,374
	Professional fees		484		749
	Other		1,923		2,082

		$	9,203	$	13,032

Business_Segment_Information_T

Business Segment Information (Tables)	9 Months Ended
Business Segment Information (Tables)	Sep. 30, 2014
Segment Reporting [Abstract]	'
Summary of Segment Information	'
	The following table summarizes segment information for the three and nine months ended September 30, 2014 and 2013:


		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Net revenues:
	OSUR	$	20,978		$	19,707		$	60,260		$	56,622
	DNAG		6,867			4,964			17,523			13,550

	Total	$	27,845		$	24,671		$	77,783		$	70,172

	Operating income (loss):
	OSUR	$	(987	)	$	(2,516	)	$	(5,177	)	$	(18,012	)
	DNAG		1,869			456			2,938			(213	)

	Total	$	882		$	(2,060	)	$	(2,239	)	$	(18,225	)

	Depreciation and amortization:
	OSUR	$	820		$	815		$	2,386		$	2,389
	DNAG		804			810			2,346			2,457

	Total	$	1,624		$	1,625		$	4,732		$	4,846

	Capital expenditures:
	OSUR	$	298		$	369		$	1,868		$	1,096
	DNAG		67			235			485			600

	Total	$	365		$	604		$	2,353		$	1,696



		September 30, 2014			December 31, 2013
	Total assets:
	OSUR	$	137,418		$	130,848
	DNAG		53,082			53,397

	Total	$	190,500		$	184,245

Presentation of Total Revenues and Long-Lived Assets by Geographic Area	'
	The following table represents total revenues by geographic area, based on the location of the customer:


		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	United States	$	22,469		$	19,052		$	58,987		$	54,052
	Europe		3,252			2,540			10,935			7,823
	Other regions		2,124			3,079			7,861			8,297

		$	27,845		$	24,671		$	77,783		$	70,172


	The following table represents total long-lived assets by geographic area:


		September 30, 2014			December 31, 2013
	United States	$	16,802		$	16,925
	Canada		1,139			975
	Other regions		17			33

		$	17,958		$	17,933

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Jul. 31, 2014

Nov. 21, 2013

Sep. 30, 2014

Customer

Securities

Up Front Payment Arrangement [Member]

AbbVie [Member]

Collaboration Agreement [Member]

Guaranteed Investment Certificates [Member]

Accounts Receivable [Member]

Maximum [Member]

Minimum [Member]

DNA Genotek [Member]

Securities

Customer Concentration Risk [Member]

Building [Member]

Computer Equipment [Member]

Machinery and Equipment [Member]

Furniture and Fixtures [Member]

Building [Member]

Computer Equipment [Member]

Machinery and Equipment [Member]

Furniture and Fixtures [Member]

Product Information [Line Items]

Available-for-sale securities, amortized cost

$5,000

Available-for-sale securities, fair value

5,000

Available-for-sale securities

Fair value of plan assets

1,090

677

Estimated useful lives of assets

'40 years

'10 years

'20 years

'2 years

Accumulated depreciation of property and equipment

30,603

28,390

Amount of goodwill at period end

22,562

23,782

Payments received for sale of exclusive rights

75,000

Additional annual payments to be received for sale of exclusive rights

55,500

3,500

Expiration date of rights agreement

31-Dec-19

Revenue recognition, milestone method description

'We could be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31,2015.

Reserve for sales return and allowances

398

279

Gain on contract termination settlement

5,500

8,300

5,500

Contract Supply service agreement period

'5 years

Deferred revenue

11,540

1,119

713

1,119

10,827

Deferred revenue payment received

15,000

Number of customers, accounted for significant concentrations

Percentage of concentration risk

12.00%

Concentration rate of accounts receivable

10.00%

Concentration rate of net revenues

10.00%

Number of third-party suppliers to manufacture DNAG's products

Number of anti-dilutive securities excluded from EPS computation

2,647

5,499

3,313

5,324

Accumulated foreign currency adjustments included in other comprehensive loss amounted

$2,451

$1,709

$2,451

$1,709

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Inventories (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Inventory, Net [Abstract]	'	'
Raw materials	$6,772	$6,700
Work in process	937	833
Finished goods	7,134	3,911
Inventories	$14,843	$11,444

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Gross	$34,620	$36,714
Accumulated Amortization	-15,789	-14,488
Net	18,831	22,226
Customer List [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'10 years	'10 years
Gross	11,190	11,795
Accumulated Amortization	-3,370	-2,701
Net	7,820	9,094
Patents and Product Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross	10,449	10,449
Accumulated Amortization	-7,844	-7,466
Net	2,605	2,983
Patents and Product Rights [Member] \| Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'3 years	'3 years
Patents and Product Rights [Member] \| Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'10 years	'10 years
Acquired Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'7 years	'7 years
Gross	8,692	9,162
Accumulated Amortization	-3,682	-2,952
Net	5,010	6,210
Tradename [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'15 years	'15 years
Gross	4,289	4,521
Accumulated Amortization	-893	-715
Net	3,396	3,806
Non-compete Agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross	'	787
Accumulated Amortization	'	-654
Net	'	$133
Non-compete Agreements [Member] \| Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'	'1 year
Non-compete Agreements [Member] \| Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization Period (Years)	'	'3 years

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings (Loss) per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
NET INCOME (LOSS)	$1,140	($1,892)	($1,962)	($17,403)
Weighted average shares of common stock outstanding:	'	'	'	'
BASIC	56,018	55,592	55,897	55,534
Dilutive effect of stock options and restricted stock	648	'	'	'
Diluted	56,666	55,592	55,897	55,534
BASIC	$0.02	($0.03)	($0.04)	($0.31)
DILUTED	$0.02	($0.03)	($0.04)	($0.31)

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	9 Months Ended
Share data in Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total compensation cost	$4,284,000	$4,187,000
Net cash proceeds from the exercise of stock options	546,000	317,000
Income tax benefit realized from stock option exercises during period	0	0
Restricted Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total compensation cost	1,998,000	2,159,000
Vesting of restricted shares, withheld and withholding obligations	106	122
Restricted shares of common stock, aggregate values	639,000	817,000
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total compensation cost	2,286,000	2,028,000
Net cash proceeds from the exercise of stock options	$546,000	$317,000

Accrued_Expenses_Schedule_of_A

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities, Current [Abstract]	'	'
Payroll and related benefits	$5,093	$5,827
Royalties	1,703	4,374
Professional fees	484	749
Other	1,923	2,082
Accrued Expenses, Total	$9,203	$13,032

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Foreign deferred tax expense (benefits)	$10,000	($127,000)	($33,000)	($786,000)
U.S. federal income tax benefits	0	0	0	0
U.S. state income tax benefits	$0	$0	$0	$0

Business_Segment_Information_A

Business Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2014
	Segment
Segment Reporting [Abstract]	'
Number of reportable segments of company	2

Business_Segment_Information_S

Business Segment Information - Summary of Segment Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	$27,845	$24,671	$77,783	$70,172	'
Operating income (loss)	882	-2,060	-2,239	-18,225	'
Depreciation and amortization	1,624	1,625	4,732	4,846	'
Capital expenditures	365	604	2,353	1,696	'
Total assets	190,500	'	190,500	'	184,245
OSUR [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	20,978	19,707	60,260	56,622	'
Operating income (loss)	-987	-2,516	-5,177	-18,012	'
Depreciation and amortization	820	815	2,386	2,389	'
Capital expenditures	298	369	1,868	1,096	'
Total assets	137,418	'	137,418	'	130,848
DNAG [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	6,867	4,964	17,523	13,550	'
Operating income (loss)	1,869	456	2,938	-213	'
Depreciation and amortization	804	810	2,346	2,457	'
Capital expenditures	67	235	485	600	'
Total assets	$53,082	'	$53,082	'	$53,397

Business_Segment_Information_P

Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'	'
Revenues	$27,845	$24,671	$77,783	$70,172	'
Long-lived assets	17,958	'	17,958	'	17,933
United States [Member]	'	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'	'
Revenues	22,469	19,052	58,987	54,052	'
Long-lived assets	16,802	'	16,802	'	16,925
Europe [Member]	'	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'	'
Revenues	3,252	2,540	10,935	7,823	'
Other Regions [Member]	'	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'	'
Revenues	2,124	3,079	7,861	8,297	'
Long-lived assets	17	'	17	'	33
Canada [Member]	'	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'	'
Long-lived assets	$1,139	'	$1,139	'	$975